Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Roesch

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 23, 2020
The predictive and prognostic significance of cell-free DNA concentration in melanomaR Váraljai, S Elouali, S S Lueong, et al.
The Science of the Total Environment|November 26, 2025
Diverging effects of global change on future invasion risks of Agama picticauda between invaded regions: Same problem, different solutionsNicolas Dubos, Steven Calesse, Kathleen C Webster, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trialE Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
ESMO Open|May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE Livingstone, H J Gogas, L Kandolf, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2019
Sequence-dependent cross-resistance of combined radiotherapy plus BRAF<sup>V600E</sup> inhibition in melanomaB Shannan, J Matschke, H Chauvistré, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 23, 2020
The predictive and prognostic significance of cell-free DNA concentration in melanomaR Váraljai, S Elouali, S S Lueong, et al.
The Science of the Total Environment|November 26, 2025
Diverging effects of global change on future invasion risks of Agama picticauda between invaded regions: Same problem, different solutionsNicolas Dubos, Steven Calesse, Kathleen C Webster, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trialE Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
ESMO Open|May 9, 2025
Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE Livingstone, H J Gogas, L Kandolf, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2019
Sequence-dependent cross-resistance of combined radiotherapy plus BRAF<sup>V600E</sup> inhibition in melanomaB Shannan, J Matschke, H Chauvistré, et al.
Pageof 6